Analysts Offer Insights on Healthcare Companies: GlaxoSmithKline (GSK) and Savara (SVRA)
TipRanks (Fri, 29-May 10:50 AM ET)
FDA to cut animal testing in cancer drug development
Seeking Alpha News (Fri, 29-May 10:09 AM ET)
TipRanks (Fri, 29-May 9:40 AM ET)
TipRanks (Fri, 29-May 5:39 AM ET)
GlaxoSmithKline (GSK) Gets a Hold from UBS
TipRanks (Fri, 29-May 5:00 AM ET)
GSK’s mRNA Flu Vaccine Trial Reaches Key Phase 2 Milestone, Eyeing Next-Gen Seasonal Market
TipRanks (Thu, 28-May 12:30 PM ET)
J.P. Morgan Keeps Their Sell Rating on GlaxoSmithKline (GSK)
TipRanks (Thu, 28-May 7:59 AM ET)
GSK, Ionis mark late-stage trial win for chronic hepatitis B therapy
Seeking Alpha News (Thu, 28-May 7:12 AM ET)
Positive Report for GlaxoSmithKline (GSK) from Kepler Capital
TipRanks (Thu, 28-May 3:55 AM ET)
GSK’s Long-Acting HIV Study Nears the Finish Line: What Investors Should Watch
TipRanks (Wed, 27-May 12:30 PM ET)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
GSK PLC American Depositary Shares (Each Representing Two Ordinary Shares) trades on the NYSE stock market under the symbol GSK.
As of May 29, 2026, GSK stock price declined to $50.54 with 2,644,262 million shares trading.
GSK has a beta of 0.41, meaning it tends to be less sensitive to market movements. GSK has a correlation of 0.03 to the broad based SPY ETF.
GSK has a market cap of $101.46 billion. This is considered a Large Cap stock.
Last quarter GSK PLC American Depositary Shares (Each Representing Two Ordinary Shares) reported $10 billion in Revenue and $1.25 earnings per share. This beat revenue expectation by $109 million and exceeded earnings estimates by $.08.
In the last 3 years, GSK traded as high as $61.70 and as low as $31.72.
The top ETF exchange traded funds that GSK belongs to (by Net Assets): AVDE, FENI, PPH, FVD, AVIV.
GSK has outperformed the market in the last year with a return of +33.6%, while the SPY ETF gained +30.0%. However, in the most recent history, GSK shares have underperformed the stock market with its stock returning -13.7% in the last 3 month period and +1.0% for the last 2 week period, while SPY has returned +10.5% and +1.1%, respectively.
GSK support price is $50.66 and resistance is $51.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GSK shares will trade within this expected range on the day.